NINDS Director emails about NIH enrollment criteria today

Author:

Several ‪#‎MECFS‬ advocates including my husband Bob received an email this afternoon from Dr. Walter Koroshetz, NINDS Director, about the NIH Clinical Study:


Dear colleagues,
Thank you for communicating your concerns. Having spoken to multiple patients with ME/CFS we believe that some of the concerns about the NIH intramural ME/CFS protocol are due to miscommunication on our part.
Please see posted notice. http://www.nih.gov/mecfs/eligibility-requirements-me/cfs-clinical-study-nih
Note that the NIH intent was always that the ME/CFS patients enrolled in the NINDS study would have post exertional malaise and qualify under multiple consensus criteria including the Canadian crieria. Reeves was being used only for stratification purposes. A detailed protocol will be posted soon.
We look forward to working together with the ME/CFS community to develop the science that leads to meaningful solutions for those who are suffering.
Best wishes,
Walter
Walter J. Koroshetz, M.D.
Director, National Institute of Neurological Disorders and Stroke

Facebook
Twitter
WhatsApp
Email

Latest News

Text across top of image reads: "Experts in infection associated chronic illness" with "WE WANT YOU!" bolded below it. Hand with finger pointed out at viewer. "Apply now" buttons to the left and right with mouse cursor clicking on them.

Infection-associated chronic disease experts needed at ARPA-H

Congress launched ARPA-H (the Advanced Research Projects Agency for Health) this past March to focus on high-risk, high-reward research projects with the goal to solve intractable health problems. As ARPA-H is in the process of hiring its first cohort of program managers, #MEAction and a coalition of chronic disease advocacy groups have published an open

Read More »

Help keep our work going

We rely on donations from people like you to keep fighting for equality for people with ME.

Donate

Get actions alerts and news direct to your inbox

You can choose what you want to be kept up to date on.

Subscribe
Scroll to Top